It does not produce 1522% body weight loss
or persistent vomiting preventing adequate fluid intake
Tirzepatide, sold under the brand name Mounjaro, is a newer medication that combines the benefits of two powerful hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide)
There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]
GLP-1 Clinical Trials Show Promising Reduction in Body Weight The most cited GLP-1 study is the STEP 1 trial , which evaluated semaglutide, the active ingredient in Wegovy, in non-diabetic adults with obesity
Clinical studies suggest Zepbound may lead to greater average weight loss for some patients, but the best choice depends on your medical history, goals, side effects, insurance coverage, and response to treatment